On Friday, Shares of Micron Technology, Inc. (NASDAQ:MU), subtract -0.68% and closed at $17.61 in the last trading session. The last trading range of the stock ranges between $17.30 and $17.80. The company’s Market capitalization is $18.32 Billion with the total Outstanding Shares of 1.04 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $9.31 and reached to max level of $19.30. Micron Technology, Inc., (MU) recently declared results of operations for its fourth quarter and 2016 fiscal year, which ended September 1, 2016. Revenues for the fourth quarter of fiscal 2016 were $3.22 billion and were 11 percent higher contrast to the third quarter of fiscal 2016 and 11 percent lower contrast to the fourth quarter of fiscal 2015. Revenues for fiscal year 2016 were $12.40 billion and net loss attributable to Micron shareholders was $276 million, or ($0.27) per diluted share. On a non-GAAP basis, the fiscal year result was income of $0.06 per diluted share. Cash flows from operations were $3.17 billion for fiscal year 2016.
“We are seeing improving market conditions in terms of both slowing supply growth and improving demand across a number of key segments,” said Micron CEO Mark Durcan. “In addition, we continue to execute on our key programs related to the deployment of advanced technologies and products to advantage our customers.”
Apple Inc. (NASDAQ:AAPL), jumped 0.15% and closed at $114.06 in the last trading session. The last trading range of the stock ranges between $113.51 and $114.56. The company’s Market capitalization is $619.17 Billion with the total Outstanding Shares of 5.39 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $89.47 and reached to max level of $123.82. Attorneys from Dallas’ Caldwell Cassady & Curry have won another multimillion-dollar patent infringement award for Nevada-based VirnetX Holding Corp. (NYSE MKT: VHC) against technology giant Apple Inc. (AAPL) based on an East Texas jury’s finding that Apple owes more than $302 million in royalties for infringing internet security patents owned by VirnetX.
Jurors in the Tyler, Texas, courtroom of Judge Robert W. Schroeder III delivered the verdict in favor of VirnetX on Sept. 30 after one week of trial. The case is VirnetX Inc., et al. v. Apple Inc., No. 6:10-CV-417, in the U.S. District Court for the Eastern District of Texas.
Caldwell Cassady & Curry name principals Bradley W. Caldwell, Jason D. Cassady and J. Austin Curry led the team representing VirnetX. The company also called on Johnny Ward from Ward, Smith & Hill, PLLC, in Longview and attorneys from Parker, Bunt & Ainsworth, P.C., of Tyler. Also representing VirnetX from Caldwell Cassady & Curry were firm principal Justin T. Nemunaitis and firm attorneys Hamad M. Hamad, Warren J. McCarty, Jason S. McManis, Daniel R. Pearson, Christopher S. Stewart, and John F. Summers.
On the other hand share Great Basin Scientific Inc (NASDAQ:GBSN),lost -53.28% and closed at $0.135 in the last trading session. The last trading range of the stock ranges between $0.12 and $0.29. The company’s Market capitalization is $233,000.00 Billion with the total Outstanding Shares of 803,437.00 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $0.12 and reached to max level of $45,025.21. Great Basin Scientific, Inc., a molecular diagnostic testing company, develops and commercializes molecular diagnostic systems that are designed to test hospital-attained infections. The companys platform provides C. diff test, a rapid medical diagnostic test for the detection of C. diff, a gram-positive bacteria that causes severe diarrhea and other intestinal disorders. It also provides Group B streptococcus test, which is used to detect Group B streptococcus from an anal/vaginal swab of a pregnant woman. The companys assays in clinical trials include Staphylococcus identification and resistance blood infection panel that is designed to identify species of staphylococcus infections, detect the mecA gene that confers drug resistance directly from positive blood cultures, and provide information on the antibiotic resistance profile of the bacteria; and Shiga toxin producing Escherichia coli (E. coli) test that identifies shiga toxin produced by E. coli. Its assays under development include Staphyloccocus aureus (SA) pre-surgical nasal screen, a rapid test for the presence of SA in the nasal passages of a pre-surgical patient; Stool bacterial pathogenic panel, which is designed to detect the causes of food poisoning; Candida blood infections panel that is designed to identify the five species of Candida directly from positive blood cultures; Pertussis test for contagious respiratory disease caused by the bacterium Bordetella pertussis; and CT/NG test for chlamydia tracomatis/neisseria gonorrhoeae.